Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds hapten – hapten-carrier complex – or...
Reexamination Certificate
2004-11-12
2009-06-30
Mondesi, Robert B (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds hapten, hapten-carrier complex, or...
C424S169100, C424S164100, C424S150100, C424S130100, C424S193100, C424S184100, C424S192100, C424S195110, C424S234100
Reexamination Certificate
active
07553490
ABSTRACT:
This invention relates to conjugates of the O-specific polysaccharide ofE. coliO157 with a carrier, and compositions thereof, and to methods of using of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (→3)-α-DGalpNAc-(1→2)-α-D-PerpNAc-(1→3) -α-L-Fucp-(1→4)-β-D-Glcp-(1→), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causingE. coli, in particularE. coliO157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity againstE. coli, in particularE. coliO157, and are useful to prevent and/or treat illnesses caused byE. coliO157.The invention further relates to the antibodies which immunoreact with the O-specific polysaccharide ofE. coliO157 and/or the carrier, that are induced by these conjugates and/or compositions thereof. The invention also relates to methods and kits using one or more of the polysaccharides, conjugates or antibodies described above.
REFERENCES:
patent: 4141970 (1979-02-01), Chidlow et al.
patent: 4356170 (1982-10-01), Jennings et al.
patent: 4711779 (1987-12-01), Porro et al.
patent: 5153312 (1992-10-01), Porro
patent: 5204097 (1993-04-01), Arnon et al.
patent: 5306492 (1994-04-01), Porro
patent: 5354661 (1994-10-01), Doyle et al.
patent: 5370872 (1994-12-01), Cryz et al.
patent: 5371197 (1994-12-01), Marburg et al.
patent: 5445817 (1995-08-01), Schneerson et al.
patent: 5512282 (1996-04-01), Krivan et al.
patent: 5552144 (1996-09-01), Samuel et al.
patent: 5585100 (1996-12-01), Mond et al.
patent: 5693326 (1997-12-01), Lees
patent: 5747272 (1998-05-01), O'Brien et al.
patent: 5773007 (1998-06-01), Penney et al.
patent: 5785973 (1998-07-01), Bixler et al.
patent: 5955293 (1999-09-01), Keusch et al.
patent: 6080400 (2000-06-01), Williams et al.
patent: 6162441 (2000-12-01), Chae et al.
patent: 6204004 (2001-03-01), Kaper et al.
patent: 6255458 (2001-07-01), Lonberg et al.
patent: 6310043 (2001-10-01), Bundle et al.
patent: 6365723 (2002-04-01), Blattner et al.
patent: 6410024 (2002-06-01), Burnie et al.
patent: 6472506 (2002-10-01), Moreau et al.
patent: 6652857 (2003-11-01), Williams et al.
patent: 6858211 (2005-02-01), Szu et al.
patent: 7135175 (2006-11-01), Castric
patent: 7247307 (2007-07-01), Szu et al.
patent: 2002/0012658 (2002-01-01), Williams et al.
patent: 2002/0160005 (2002-10-01), Tzipori et al.
patent: 2003/0065145 (2003-04-01), Burnie et al.
patent: 2003/0166841 (2003-09-01), Kaper et al.
patent: 2003/0170248 (2003-09-01), Stinson et al.
patent: 2005/0158339 (2005-07-01), Szu et al.
patent: 2005/0271675 (2005-12-01), Schneerson et al.
patent: 2006/0161996 (2006-07-01), Ishikawa et al.
patent: 91/01755 (1991-02-01), None
Bell, Peth P et al, Pediatrics, vol. 100(No. 1), Jul. 1, 1997, pp. 1-6.
Konadu, E et al, Chapter 42, pp. 419-424, Synthesis and immunologic properties of O-specific polysaccharide-protein conjugate vaccines for prevention and treatment of infections withEscherichia coliO157 and other causes of Hemolytic-uremic syndrome. American Society of Microbiology, 1998.
Greatorex, Jane S. et al, Journal of Clinical Microbiology, vol. 32(5), pp. 1172-1178, May 1994, Humoral immune responses to Shiga-like toxins andEscherichia coliO157 Lipoppolysaccharide in Hemnolytic Uremic Syndrome Patients and Healthy subjects.
Cook, SR et al, Journal of Applied Microbiology, vol. 103, pp. 1206-1219, 2007.
Paton, Adrienne W. et al, Microbial Pathogenesis, 1998, vol. 24, pp. 57-63.
Reymond, D et al, Journal of Clinical Microbiology, vol. 34(9),Sep. 1996, pp. 2053-2057.
Greatorex, Jane S. et al, J. Clin. Microbiology, vol. 32(5), pp. 1172-1178, May 1994.
Ashkenazi et al, 1988, reference of record.
Chart et al, reference of record.
Konadu et al, 1994, reference of record.
Robbins et al, reference of record.
Perry et al, J. Clin. Microbiology, Nov. 1988, vol. 26(11), pp. 2391-2394.
Vernozy-Rozand, C, J. Applied Microbiology, May 1997, vol. 82(5), pp. 537-551.
Louise, CB et al, Infection and Immunity, vol. 60(4), pp. 1536-1543, Apr. 1992.
Chart et al., “Antibody Cross-Reactions with Lipopolysaccharide fromE coliO157 After Cholera Vaccination,”Lancent 341:1282 (1993).
Cohen et al., “Safety and Immunogenicity of InvestigationalShigellaConjugate Vaccines in Israeli Volunteers,”Infect. Immun. 64:4074-4077 (1996).
Cohen et al., “Double-Blind Vaccine-Controlled Randomised Efficacy Trial of an InvestigationalShigella sonneiConjugate Vaccine in Young Adults,”Lancet 349:155-159 (1997).
Fattom et al., “Serum Antibody Response in Adult Volunteers Elicited by Injection ofStreptococcus pneumoniaeType 12F Polysaccharide Alone or Conjugated to Diphtheria Toxoid,”Infect. Immun. 58:2309-2312 (1990).
Greatorex et al., “Humoral Immune Responses to Shiga-Like Toxins andEscherichia coliO157 Lipopolysaccharide in Hemolytic-Uremic Syndrome Patients and Healthy Subjects,”J. Clin. Microbiol. 32:1172-1178 (1994).
Konadu et al., “Synthesis, Characterization, and Immunological Properties in Mice of Conjugates Composed of Detoxified Lipopolysaccharide ofSalmonella paratyphiA Bound to Tetanus Toxoid, with Emphasis on the Role ofOAcetyls,”Infect. Immun. 64:2709-2715 (1996).
Robbins et al., “Polysaccharide-Protein Conjugates: A New Generation of Vaccines,”J. Infect. Dis. 161:821-832 (1990).
Szu et al., “Vi Capsular Polysaccharide-Protein Conjugates for Prevention of Typhoid Fever,”J. Exp. Med 166:1510-1524 (1987).
Ashkenazi et al., “Anticytotoxin-Neutralizing Antibodies in Immune Globulin Preparations: Potential Use in Hemolytic-Uremic Syndrome,”J. Pediatr. 113:1008-1014 (1988).
Bitzan et al., “Differences in Verotoxin Neutralizing Activity of Therapeutic Immunoglobulins and Sera from Health Controls,”Infection 21:140-145 (1993).
Brief Notes: Researchers at the National Institutes of Health,Food Chemical News, vol. 39, No. 52, (Abstract), Feb. 16, 1998).
Chart et al., “Serum Antibodies toEscherichia coliSerotype O157:H7 in Patients with Hemolytic Uremic Syndrome,”J. Clin. Microbiol. 27:285-290 (1989).
Chu et al., “Preparation, Characterization, and Immunogenicity of Conjugates Composed of the O-Specific Polysaccharide ofShigella dysenteriaeType 1 (Shiga's Bacillus) Bond to Tetanus Toxoid,”Infect. Immun. 59:4450-4458 (1991).
Claesson et al., “Clinical and Immunologic Responses to the Capsular Polysaccharide of Haemophilus Influenzae Type b Alone or Conjugated to Tetanus Toxoid in 18- to 23-Month Old Children,”J. Pediatr. 112:695-702 (1988).
Conference Discusses Ways to ReduceE. coliat Farm and Slaughter,Food Chemical News, vol. 37, No. 9 (Abstract), Apr. 24, 1995.
Conlan et al., “Parenteral Immunization with a Glycoconjugate Vaccine Containing the O157 Antigen ofEscherichia coliO157:H7 Elicits a Systemic Humoral Immune Response in Mice, but Fails to Prevent Colonization by the Pathogen,”Can. J. Microbiol. Rev. 45:279-286 (1999). Abstract only.
Cryz, Jr. et al., “Synthesis and Characterization ofEscherichia coliO18 O-Polysaccharide Conjugate Vaccines,”Infect. Immun. 58:373-377 (1990).
Cryz, Jr. et al., “Safety and Immunogenicity ofEscherichia coliO18 O-Specific Polysaccharide (O-PS)-Toxin A and O-PS-Cholera Toxin Conjugate Vaccines in Humans,”J. Infect. Dis. 163:1040-1045 (1991).
Dick and Beurret, “Glycoconjugates of Bacterial Carbohydrate Antigens. A Survey and Consideration of Design and Preparation Factors,”Contrib. Microbiol. Immunol. 10:48-114 (1989).
E. coli, VTEC Research Reviewed at IAMFES Meeting,Food Chemical News, vol. 38, No. 21 (Abstract), Jul. 15, 1996.
E. coliUS Ex
Konadu, legal representative Yvonne Ageyman
Robbins John B.
Szu Shousun Chen
Klarquist & Sparkman, LLP
Mondesi Robert B
Portner Ginny
The United States of America as represented by the Secretary of
LandOfFree
Vaccines against Escherichia coli O157 infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccines against Escherichia coli O157 infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccines against Escherichia coli O157 infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4080925